GlassScriptPhysician profile
Enobong C Udo
NPI 1124518253
$3,860.79
in general payments reported to CMS, 2019-2025
28 companies · $84.05 in 2025
The $84.05 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,853 · 2022: $1,394 · 2023: $530 · 2025: $84.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.88 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $418.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $373.99 | 2022 | |
| Grt US Holding, INC. | $306.66 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.22 | 2021-2023 | Relistor |
| Pacira Therapeutics, INC. | $234.37 | 2021 | |
| Amgen INC. | $223.84 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $189.28 | 2021-2023 | Ztlido |
| Biodelivery Sciences International, INC. | $187.69 | 2021 | |
| Spinal Simplicity, LLC | $144.37 | 2023 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $143.61 | 2022-2023 | Belbuca |
| Horizon Therapeutics Plc | $119.11 | 2021-2022 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Upsher-Smith Laboratories LLC | $79.84 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $63.95 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.84 | 2021 | |
| Pfizer INC. | $50.67 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $49.78 | 2021-2023 | Ajovy |
| Almatica Pharma LLC | $47.29 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Ibsa Pharma INC. | $37.78 | 2021-2022 | |
| Redhill Biopharma INC. | $35.85 | 2021 | |
| Averitas Pharma INC. | $24.89 | 2023 | Qutenza |
| Boston Scientific Corporation | $21.71 | 2021 | |
| Abbott Laboratories | $19.88 | 2022 | |
| Avanos Medical | $14.08 | 2022 | |
| Dexcom, INC. | $12.95 | 2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $12.77 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enobong Udo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.